DEA to Establish 2026 Annual Production Quotas for Certain Controlled Substances
The Drug Enforcement Administration proposes to establish the 2026 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine and phenylpropanolamine, a Federal Register notice says. Comments are due by Dec. 15.
Sign up for a free preview to unlock the rest of this article
If your job depends on informed compliance, you need International Trade Today. Delivered every business day and available any time online, only International Trade Today helps you stay current on the increasingly complex international trade regulatory environment.
DEA says the proposed 2026 quotas represent those quantities of schedule I and II controlled substances, and the list I chemicals ephedrine, pseudoephedrine and phenylpropanolamine to be manufactured in the U.S. in 2026 for estimated medical, scientific, research and industrial needs, lawful export requirements and the establishment and maintenance of reserve stocks. These quotas include imports of ephedrine, pseudoephedrine and phenylpropanolamine, but don't include imports of controlled substances for use in industrial processes, DEA said.